Ammonium tetrathiomolybdate treatment of copper-associated hepatopathy in dogs

Daniel K. Langlois1 | Janice R. Querubin1 | William D. Schall1 | Nathan C. Nelson1 | Rebecca C. Smedley2

1Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan
2Veterinary Diagnostic Laboratory, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan

Correspondence
Daniel K. Langlois, Department of Small Animal Clinical Sciences, Michigan State University College of Veterinary Medicine, 736 Wilson Road, East Lansing, MI 48824. Email: langlo21@cvm.msu.edu

Present address
Nathan C. Nelson, Department of Molecular Biomedical Sciences, North Carolina State University College of Veterinary Medicine, Raleigh, NC 27607.

Abstract

Background: Copper-associated hepatopathy (CAH) is a common cause of liver disease in dogs. Although D-penicillamine can be an effective treatment, some dogs fail treatment or develop adverse effects. Ammonium tetrathiomolybdate (TTM) has been used to treat pathologic copper accumulation in other species, but its therapeutic potential for CAH is unknown.

Objectives: To investigate short-term safety and efficacy of TTM for treatment of CAH.

Animals: Ten dogs with CAH.

Methods: Prospective study. All dogs were treated with TTM PO for 6 weeks, and hepatic biopsies were performed after the treatment course. Dog experiencing initial decreases in hepatic copper concentrations ([Cu]H) received 6 additional weeks of TTM treatment and underwent 1 additional biopsy. Physical and laboratory examinations were performed every 2 weeks for study duration.

Results: Eight of 10 dogs had decreases in [Cu]H. Compared to baseline (median, 1606 μg/g; range, 572-5158 μg/g), [Cu]H were decreased at 6 weeks (1033 μg/g, 450-2975 μg/g; P = .04) and 12 weeks (931 μg/g, 218-1677 μg/g; P = .02). Hepatic molybdenum concentrations increased >50-fold (P < 0.001). Changes in histologic scores and hematologic and biochemical test results were variable and not significantly different from baseline. One dog developed presumed immune-mediated anemia and thrombocytopenia, but it was unclear if this was related to TTM administration.

Conclusions and Clinical Importance: Results suggest that TTM can effectively decrease [Cu]H in some dogs with CAH. Larger studies are needed to determine the overall safety and efficacy of TTM for treating CAH and how it compares with current treatments.

KEYWORDS
chelation, copper toxicosis, hepatitis, Labrador Retrievers, molybdenum

INTRODUCTION

Copper-associated hepatopathy (CAH) is characterized by progressive hepatic copper accumulation leading to hepatitis, cirrhosis, and eventual...
death if left untreated. The disease has garnered considerable attention from the veterinary community in recent years. Once thought to be a rare condition affecting only Bedlington Terriers, CAH is widely recognized in Labrador Retrievers, Doberman Pinschers, West Highland White Terriers, and Dalmatians. More recently, CAH has been recognized in various breeds and crosses not typically considered predisposed to CAH. The genetic basis for disease in Bedlington Terriers is well described, but the etiology in other breeds is complex and multifactorial.

The primary goals of treatment are to decrease hepatic copper concentrations ([Cu]H) and prevent subsequent re-accumulation. Both dietary copper restriction and PO administration of zinc salts can prevent further copper accumulation in some dogs, but these treatments do not quickly affect the copper load already present in the liver. Some dogs develop gastrointestinal upset when treated with high doses of zinc salts, and some dogs continue to accumulate copper despite feeding of a copper-restricted diet. Consequently, these treatments are indicated for dogs with subclinical disease or for maintenance treatment after more aggressive treatment. D-penicillamine is considered the initial treatment of choice for most dogs with CAH including those with clinical illness and those with moderate to severe hepatic histopathologic abnormalities. It is a potent copper chelator that can rapidly induce urinary copper excretion and negative copper balance. However, it is not uniformly effective, and some dogs experience minimal or no decrease in [Cu]H despite months of treatment. Even in dogs that respond to treatment, the duration of treatment necessary to restore normal [Cu]H often exceeds 6-10 months. Anorexia and vomiting are common adverse effects, and in some instances, these can preclude d-penicillamine usage. Although d-penicillamine remains an effective drug for many dogs with CAH, these limitations warrant investigation of alternative treatments.

Ammonium tetrathiomolybdate (TTM) is a copper chelator that has proven to be an effective treatment for Wilson’s disease in humans, copper toxicity in sheep, and pathologic copper accumulation in rodents. This molybdenum salt forms a tight tripartite complex with copper and albumin, most of which then undergoes hepatobiliary excretion. It is unique because of its additive actions in the intestines, plasma, and liver. Administration of TTM to healthy dogs increases serum copper concentrations, which suggests that TTM mobilizes tissue copper. However, the use of TTM to treat dogs with CAH has not been reported. Our objectives were to determine if TTM altered [Cu]H or the extent of liver injury in dogs with CAH. The clinical, hematologic, and biochemical effects of TTM administration also were investigated. Our primary hypothesis was that TTM administration would decrease [Cu]H in dogs with CAH.

2 | MATERIALS AND METHODS

2.1 | Animals

A prospective single-arm clinical study was conducted to investigate the therapeutic potential of TTM for CAH in dogs. A sample size calculation was performed using archived data from CAH-affected dogs that underwent pre- and post-chelation biopsies in our hospital. The analysis suggested that 8 dogs would be needed to detect an approximate 350 μg/g difference in [Cu]H after chelation treatment with power of 0.8 and alpha of 0.05. Most dogs recruited to the study were expected to have mild to moderate disease based on the inclusion and exclusion criteria described below. The magnitude of decrease in [Cu]H considered to represent therapeutic improvement likely varies among clinicians and depends upon initial disease severity, but a value of 350 μg/g was thought to represent a clinically relevant decrease for this population of dogs.

Client-owned and clinically stable dogs with increased ALT activity on at least 2 occasions in the preceding 6 months and ALT activity > ALP activity were recruited from the Michigan State University Veterinary Medical Center (MSU-VMC) and surrounding general practice clinics. An initial evaluation was performed including history, physical examination, CBC (Advia 120 Hematology System; Siemens Healthcare Inc, Deerfield, Illinois), serum biochemical profile (Olympus AU640e; Olympus America Inc, Center Valley, Pennsylvania), urinalysis, and abdominal ultrasound examination. Dogs were excluded from further participation if any of the following were present: (1) vomiting >3 times per week, (2) consumption of <50% of estimated daily resting energy requirements, (3) consumption of a prescription low-copper diet, (4) increased serum bilirubin concentrations (>0.5 mg/dL), (5) increased serum creatinine concentrations (>1.6 mg/dL), or (6) sonographic evidence of neoplastic disease or gall bladder disease. Dogs not meeting exclusion criteria underwent hepatic biopsy as described below. Dogs with centrilobular to panlobular copper accumulation (rhodanine score ≥2), [Cu]H > 400 μg/g, histologic evidence of chronic hepatitis, and negative microbial cultures were considered to have CAH and enrolled in the study.

2.2 | Experimental protocol

Capsules containing powdered TTM (purity, 99.9%; Sigma-Aldrich Inc, St Louis, Missouri) were compounded by the MSU-VMC pharmacy. Dogs received TTM according to the following schedule based on body weight:

- Dogs >60 kg: 40 mg PO 4 times daily.
- Dogs 50-59.9 kg: 25 mg PO 4 times daily.
- Dogs 40-49.9 kg: 20 mg PO 4 times daily.
- Dogs 30-29.9 kg: 12.5 mg PO 4 times daily.
- Dogs 20-19.9 kg: 8 mg PO 4 times daily.
- Dogs 10-9.9 kg: 5 mg PO 4 times daily.
- Dogs 5-4.9 kg: 2.5 mg PO 4 times daily.
- Dogs <5 kg: 1.25 mg PO 4 times daily.

Capsules were prepared for each dog upon entry into the trial and again at the time of 6-week reevaluation. Analysis of random capsules by the use of inductively coupled plasma—mass spectrometry established that capsules were prepared to mean ± SD of 95.6% ± 8.8% of target dose. The TTM dosage of approximately 0.5 mg/kg was extrapolated from previous studies of humans and dogs. Owners were instructed to administer 1 dose with morning and evening meals, whereas the other 2 doses were administered on an empty stomach 1 hour before or 2 hours after meals. This dosing schedule, which is similar to those used in the treatment of humans with Wilson’s disease, was anticipated to result in both copper chelation and decreased dietary copper absorption. Owners maintained medication logs.
and recorded the time of TTM administration, amount of TTM administered, and whether TTM was administered fasted or with food. In addition, owners recorded any vomiting episodes.

A reevaluation physical examination, CBC, and serum biochemical profile were performed every 2 weeks for study duration. Hepatic biopsy was repeated in all dogs at 6 weeks. Treatment was extended for an additional 6 weeks in dogs experiencing either a >15% decrease or a >150 μg/g decrease in [Cu]H as compared to baseline, and a final biopsy was performed in these dogs at 12 weeks. Dietary changes were not allowed, and dogs were not permitted to receive ursodeoxycholic acid treatment, zinc salts, other copper chelating agents, or dietary supplements containing trace minerals for the duration of the trial. After study conclusion, dogs were transitioned to standard of care treatments at the discretion of their attending veterinarian.

2.3 | Hepatic histopathology and quantitative mineral determinations

Limited assessments of coagulation, including determination of prothrombin and activated partial thromboplastin times, were normal in all dogs before each hepatic biopsy procedure. Ultrasound-guided hepatic biopsies were performed while dogs were under general anesthesia. For each procedure, 6-7 tissue specimens were collected using a 14-gauge single action needle biopsy device (EZ Core; Products Group International Inc, Lyons, Colorado). Four specimens were fixed in 10% neutral buffered formalin, 2 specimens were placed in a mineral-free container and submitted for determination of trace mineral concentrations, and 1 specimen from the initial biopsy procedure was submitted for microbial culture. Paraffin-embedded sections of liver tissue were routinely sectioned and stained with hematoxylin and eosin (H&E) and rhodanine. The needle biopsy specimens provided approximately 20-30 portal triads for evaluation at each time point. All slides were evaluated by a single board-certified veterinary pathologist (R.C.S.) who was blinded to clinical data, timing of the sample, and quantitative mineral concentrations. The H&E-stained slides were scored for necroinflammatory activity and fibrosis (Table 1). A validated scoring system for hepatopathology in dogs does not exist, and the scoring system used herein was derived from the same sources used in previous veterinary publications.22,34-36 It closely resembles a scoring system proposed by the World Small Animal Veterinary Association Liver Standardization Group with the exception that centrilobular inflammation was treated as a distinct category, given the classic pattern of copper accumulation and inflammation in CAH.31 Briefly, scores were assigned for the severity of fibrosis (range, FO-F4), centrilobular inflammation (range, C0-C3), portal inflammation (range, PO-P3), lobular necrosis (range, L0-LN2), and piecemeal necrosis (range, PMNO-PMN3). An overall necroinflammatory activity score (NI) was obtained by adding the scores for centrilobular inflammation, portal inflammation, lobular necrosis, and piecemeal necrosis. Necroinflammatory activity scores could range from 0 to 11. Rhodanine-stained slides were assessed for copper accumulation using a previously described system with potential scores ranging from 0 (no detected copper granules) to 5 (panlobular presence of large numbers of copper granules in hepatocytes, usually associated with copper-containing macrophages).30 Quantitative hepatic copper and molybdenum concentrations (μg/g, dry matter basis) were determined on liver specimens using inductively coupled plasma-mass spectroscopy as described elsewhere.4 Hepatic molybdenum concentrations were measured because they are a potential marker for TTM.27,28 The reference intervals in our laboratory for hepatic copper and molybdenum concentrations in dogs are 137-400 μg/g and 0.8-2.3 μg/g, respectively. These reference intervals were established by evaluating the concentrations in all hepatic tissue submissions over a several-year time period and utilizing the 10%-90% range of obtained values as the normal reference interval. However, the reference interval for copper was modified to be consistent with other laboratories that have adopted 400 μg/g as the upper-end of normal given that rhodanine staining often is positive at this threshold.1-3,7,10

2.4 | Data and statistical analysis

Data sets were assessed for normality by Shapiro–Wilk testing and box plot analysis. Data that approximated normal distributions were reported as means ± SDs, whereas ordinal data and data not approximating normal distributions were reported as medians and ranges. Statistical analyses were performed to investigate potential changes in hepatic mineral concentrations, histologic scores, and hematologic and biochemical variables after TTM treatment. The effect of treatment over time on routine hematologic and biochemical variables was evaluated using a repeated-measures analysis of variance with Tukey’s post hoc testing. The effect of treatment over time on hepatic mineral concentrations and histologic scores was evaluated using Friedman testing with Dunn’s post hoc testing. Statistical analyses were performed with commercially available software (GraphPad Prism Version 6.0; GraphPad Software Inc, La Jolla, California), and for all analyses, P ≤ 0.05 was considered significant.

3 | RESULTS

3.1 | Dogs

Eleven dogs met initial inclusion criteria and were enrolled in the clinical trial, but 1 dog was removed from participation after 1 week of TTM treatment because of noncompliance with dietary guidelines. Data from this dog were not included in the study. The 10 remaining dogs included 5 Labrador Retrievers, 2 Pit Bull Terrier crosses, 1 Doberman Pinscher, 1 West Highland White Terrier, and 1 Mastiff. The median (range) age and weight of the dogs were 6 years (3-10 years) and 34.0 kg (8.7-99.0 kg), respectively. The mean ± SD initial TTM dosage for these 10 dogs was 0.56 ± 0.09 mg/kg PO 4 times daily.

Dog 1, a 3-year-old neutered male Mastiff, had been receiving prednisolone (0.3 mg/kg PO q24h) for 2.5 months for treatment of known CAH. Liver biopsy specimens from 2.5 months before enrollment and again at the time of enrollment featured centrilobular inflammation and increasing [Cu]H (1764 μg/g and 2125 μg/g, respectively). Laboratory data and histology scores from this dog were included in all analyses reported herein. The inclusion or exclusion of
**TABLE 1** Scoring system used to assess hepatic pathology

| Score Criteria | Centrilobular inflammation | Portal inflammation | Lobular necrosis | Piecemeal necrosis | Fibrosis |
|----------------|---------------------------|---------------------|-----------------|-------------------|---------|
| C0 Absent      | P0 Absent                 | LN0 <1 necroinflammatory focus per lobule | PN0 Absent       | F0 Absent         |
| C1 Mononuclear aggregates in some centrilobular areas | P1 Mononuclear aggregates in some portal tracts | LN1 At least 1 necroinflammatory focus per lobule | PN1 Focal alteration of the perportal plate in some portal tracts | F1 Portal fibrosis without septae |
| C2 Mononuclear aggregates in all centrilobular areas | P2 Mononuclear aggregates in all portal tracts | LN2 Several necroinflammatory foci per lobule or confluent or bridging necrosis | PN2 Diffuse alteration of perportal plate in some portal tracts or focal lesions around all portal tracts | F2 Portal fibrosis with rare septae |
| C3 Large and dense mononuclear aggregates in all centrilobular areas | P3 Large and dense mononuclear aggregates in all portal tracts | PN3 Diffuse alteration of the perportal plate in all portal tracts | F3 Numerous septae without cirrhosis |
| C4 Cirrhosis |

All slides were scored for necroinflammatory activity and fibrosis using the above guidelines. A composite score for necroinflammatory activity was calculated by summing the scores for centrilobular inflammation, portal inflammation, lobular necrosis, and piecemeal necrosis with potential scores ranging from 0 to 11.

This data did not affect statistical significance. Dog 6, an 8-year-old neutered male Labrador Retriever, had been receiving phenobarbital (1.8 mg/kg PO q12h) for 7 years for management of presumed idiopathic epilepsy. Hepatic biopsy specimens in this dog indicated classic CAH characterized by [Cu]_, of 2087 μg/g and a rhodanine score of 4. No evidence of phenobarbital induced hepatotoxicosis was observed. Dog 7, a 10-year-old spayed female Doberman Pinscher, had been receiving phenytoin (1.5 mg/kg PO q8h) and conjugated estrogen (0.625 mg PO q 4 days) for 8 years for urinary incontinence. Medications for these 3 dogs were continued throughout the study. No other dogs were receiving concurrent medications.

### 3.2 Clinical monitoring

Oral TTM treatment was well tolerated at the initial dosage in 8 dogs (dogs 1, 2, 3, 4, 6, 7, 8, and 9). Lethargy and anorexia were not observed in any of these dogs. Only 17 episodes of vomiting were observed out of 579 total study days for these 8 dogs which equates to an average of <1 vomiting episode per dog per month. Dog 10, a 7-year-old neutered male Labrador Retriever, vomited 5 times during the first week of treatment and had an approximate 60% decrease in food intake. The daily TTM dosage was decreased by 25%, and the dog was treated with ondansetron (0.25 mg/kg PO q12h) for the remainder of the study. No additional vomiting was observed in this dog. Dog 5, a 4-year-old spayed female Pit Bull Terrier cross, vomited on 4 occasions during the first 2 weeks of treatment. Drug administration was stopped for 2 days and restarted at the same dosage. Only 1 additional vomiting episode was observed in this dog, and appetite and energy were normal throughout the first 10 weeks of the study. This dog developed presumed immune-mediated anemia and thrombocytopenia during the 11th week of TTM treatment at which time the dog became anorexic and lethargic. Laboratory evaluation disclosed poorly regenerative anemia (hematocrit, 30%; reference interval, 41%-55%) and thrombocytopenia (19 × 10³/μL; reference interval, 160-401 × 10³/μL). Spherocytosis was not observed, but cytologic evaluation of a bone marrow aspirate disclosed increased macrophages with phagocytosed erythrocytes and erythrocyte precursors. Treatment with TTM was discontinued, and the dog was placed on a tapering course of prednisone (initial dosage, 1 mg/kg PO q12h). The dog achieved complete remission of anemia and thrombocytopenia, and the final evaluation and hepatic biopsy were performed at week 16 instead of week 12. Blood results and histologic scores for necroinflammatory activity and fibrosis from the final evaluation were not included in statistical analyses because of the recently initiated prednisone treatment. Other possible adverse events were not reported in any dogs. Long-term follow-up was not performed as part of the study, but all dogs were alive >6 months after study completion.

### 3.3 Clinicopathologic evaluations

Hematologic and serum biochemical evaluations were performed every 2 weeks for study duration (Table 2). Five of 10 dogs (dogs 3, 5, 8, 9, and 10) had decreases in serum ALT activity at week 6 as compared to baseline, but overall changes were not significant (P = .34). Serum ALT activity had increased >2-fold in 2 dogs (dogs 6 and 7) at the time of the week 6 reevaluation. These same 2 dogs did not have decreases in
Our results indicate that PO administration of TTM can lower [Cu]H in most dogs with CAH, thus providing support for continued investigations into the role of TTM in the treatment of copper-associated hepatopathy.
accumulation of copper despite feeding of a copper-restricted diet. Over 6 months of dietary copper restriction typically results in decreased copper accumulation with potential scores ranging from 0 to 5. Hematoxylin and eosin-stained slides were scored for necroinflammatory activity and fibrosis with potential scores ranging from 0 to 11 and 0 to 4, respectively.

### Histologic scores for the dogs with copper-associated hepatopathy that participated in the ammonium tetrathiomolybdate trial

| Score Type         | Baseline | Week 6 | Week 12 | P-value |
|-------------------|----------|--------|---------|---------|
| Rhodanine         | 3.5 (2-5)| 2.5 (2-5)| 2 (2-4) | .10     |
| n=10              | n=10     | n=8    |         |         |
| Necroinflammatory activity | 5 (2-10) | 5.5 (2-11) | 6 (2-10)| .99     |
| n=10              | n=10     | n=7    |         |         |
| Fibrosis          | 2 (1-3)  | 2 (0-3) | 2 (1-3) | .17     |
| n=10              | n=10     | n=7    |         |         |

Values represent the medians, and ranges are provided in parentheses. Rhodanine-stained slides were scored to further assess copper accumulation with potential scores ranging from 0 to 5. Hematoxylin and eosin-stained slides were scored for necroinflammatory activity and fibrosis with potential scores ranging from 0 to 11 and 0 to 4, respectively.

The overall decreases in [Cu]H after TTM treatment are a promising finding, but reasons for the lack of response in 2 dogs are unknown as are the reasons for the lack of continued decrease in [Cu]H at week 12. Therapeutic failures in dogs with CAH are observed with both dietary copper restriction and D-penicillamine chelation treatment. Administration of TTM can preserve life and decrease [Cu]H in rodents with severe hepatitis and copper accumulation. These findings in other species suggest that TTM could have a similar role for treating dogs with more advanced CAH.

Ammonium tetrathiomolybdate treatment of Wilson's disease is well-tolerated in most people. Conversely, D-penicillamine treatment of Wilson's disease has been associated with numerous adverse effects, which can contribute to poor patient compliance. Many of the immunologic reactions and adverse neurologic effects described in humans have not been recognized in dogs, but adverse gastrointestinal effects do occur in 20%-50% of dogs treated with D-penicillamine. Ammonium tetrathiomolybdate treatment was well tolerated in the majority of dogs with CAH in our study. Adverse gastrointestinal effects were sporadic and did not preclude treatment in any dog. Only 1 of 10 dogs required dosage modifications because of gastrointestinal upset. The most concerning potential adverse event was the development of immune-mediated anemia and thrombocytopenia in 1 dog. Tetrathiomolybdate can induce various hematologic abnormalities in humans including anemia and leukopenia. These abnormalities are a consequence of copper deficiency in the bone marrow as opposed to immune-mediated destruction of erythroid or myeloid cells. Consequently, it is unknown if the anemia and thrombocytopenia observed in the dog were caused by TTM or whether abnormalities occurred independent of TTM treatment.

Liver enzyme activities and histologic scores remained static despite decreases in [Cu]H. These results are similar to a study of D-penicillamine-treated Labrador Retrievers with CAH in which liver enzyme activities and fibrosis scores were unchanged, and although median necroinflammatory activity scores decreased, some individual dogs had worsening necroinflammatory scores. Reasons for the lack of changes in our study are likely complex and multifactorial. The decreases in [Cu]H were of clinical relevance in most dogs, but they were unlikely to be of the magnitude necessary to completely ameliorate hepatocyte injury. Many patients with Wilson's disease receiving TTM also experience increased ALT activity during initial treatment, which is thought to be a result of increased copper mobilization during the initial phases of treatment. Similar to our study, serum markers of liver function usually remain normal in these patients. The lack of decrease in histology scores and liver enzyme activities could be perceived as a discouraging finding, but it is important to note that these variables did not worsen. Treatment with TTM may have stabilized disease in some dogs and prevented further progression of liver injury, but this conclusion is speculative pending additional investigation.
in dogs, and continued treatment may not confer additional benefit. More detailed studies of TTM are needed to address these possibilities and clarify potential roles of TTM for treatment of CAH.

The antagonistic and inverse relationships between molybdenum and copper are well described, and it is possible that TTM efficacy could correlate with tissue molybdenum concentrations. However, the limited sample size and variable results precluded meaningful assessment of potential relationships between hepatic copper and molybdenum. The increases in hepatic molybdenum concentrations were pronounced, and some dogs experienced >50-fold increases after TTM treatment. The effects of this degree of accumulation, if any, are unknown. Some of the hepatic molybdenum likely was complexed with copper in an inactive form. There may be benefit of TTM treatment beyond solely decreasing [Cu]H because TTM bound copper, even if still present within hepatic tissue, would not be expected to result in tissue injury. However, excess tissue molybdenum could be pathologic. Molybdenum toxicosis typically results in abnormalities consistent with copper deficiency such as hyporegenerative anemia and leukopenia. Infrequently, molybdenum can have a direct hepatotoxic effect. Furthermore, the ultimate consequences of accumulated molybdenum within liver or other tissues of dogs with CAH are unknown. Hepatic molybdenum concentrations decrease several months after experimental TTM treatment of sheep with variable hepatic copper status. However, molybdenum was retained for months to years in organs such as brain, pituitary gland, and adrenal glands. This accumulation was speculated to result in endocrine dysfunction, generalized ill thrift, and infertility. Similar abnormalities have not been reported in patients with Wilson’s disease treated with TTM.

The etiology of CAH in most breeds of dogs is complex and poorly characterized, but dietary copper likely is involved in the pathogenesis. Dietary copper concentrations were not investigated as part of our study, and it is possible that TTM responsiveness was influenced by dietary copper. Feeding of a standardized diet before and during the study may have resulted in more uniform and consistent responses. Although this factor should be considered in future studies, dietary changes were not permitted during the course of the study to prevent changing exposure levels within individual dogs. A limitation hampering clinical use of TTM in companion animal medicine is that TTM is not commercially available as a pharmaceutical grade product. Copper chelation with TTM is an active area of research for treatment of various oncologic and neurologic disorders in humans, and commercial products could become available pending continued evaluations. Also, high purity analytical grade TTM is inexpensive and available from several chemical supply companies (Sigma-Aldrich Inc). Practitioners have used such formulations for decades to treat copper poisoning in sheep. The dosing schedule for TTM may not be practical for some dog owners. This protocol was chosen because it was comparable to those used in humans with Wilson’s disease, and it would be most likely to result in a detectable clinical effect. Alternate dosing strategies might lessen compliance concerns and still result in efficacy. Indeed, an experimental formulation of tetrathiomolybdate that requires once daily dosing is currently in development for humans with Wilson’s disease.

In conclusion, TTM treatment resulted in decreases in [Cu]H in most dogs with CAH. The decreases in copper load after TTM treatment might be of greater magnitude than the decreases observed with other commonly used treatments. The lack of changes in histology scores and liver enzyme activities require further study as does the possibility for immunologic reactions such as may have occurred in 1 dog. Adverse gastrointestinal effects were mild in most dogs, and only 1 dog required a dose reduction because of gastrointestinal upset. In the aggregate, these results provide support for continued investigation of TTM as a treatment for CAH in dogs.

ACKNOWLEDGMENT

Portions of this work have been presented in poster form at the Michigan State University College of Veterinary Medicine annual Phi Zeta Research Day in October, 2016.

CONFLICT OF INTEREST DECLARATION

Authors declare no conflict of interest.

OFF-LABEL ANTIMICROBIAL DECLARATION

Authors declare no off-label use of antimicrobials.

INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC) OR OTHER APPROVAL DECLARATION

This study was approved by the Michigan State University IACUC, and informed consent was obtained from all dog owners.

HUMAN ETHICS APPROVAL DECLARATION

Authors declare human ethics approval was not needed for this study.

ORCID

Daniel K. Langlois https://orcid.org/0000-0001-7726-6307
Nathan C. Nelson https://orcid.org/0000-0003-3765-1694

REFERENCES

1. Dirksen F, Fieten H. Canine copper-associated hepatitis. Vet Clin North Am Small Anim Pract. 2017;47:631-644.
2. Hoffman G. Copper-associated liver diseases. Vet Clin North Am Small Anim Pract. 2009;39:489-511.
3. Johnston AN, Center SA, McDonough SP, et al. Hepatic copper concentrations in Labrador Retrievers with and without chronic hepatitis: 72 cases (1980-2010). J Am Vet Med Assoc. 2013;242:372-380.
4. Stuckland JM, Buchweitz JP, Smelley RC, et al. Hepatic copper concentrations in 546 dogs (1982-2015). J Vet Intern Med. 2018;32:1943-1950.
5. Smelley R, Mullaney T, Rumbeiha W. Copper-associated hepatitis in Labrador Retrievers. Vet Path. 2009;46:484-490.
6. Hardy RM, Stevens JB, Stowe CM. Chronic progressive hepatitis in Bedlington Terriers associated with elevated liver copper concentrations. Minnesota Veterinarian. 1975;15:13-24.
7. Hoffmann G, van den Ingh TS, Bode P, et al. Copper-associated chronic hepatitis in Labrador Retrievers. *J Vet Intern Med.* 2006;20:856-861.

8. Langlois DK, Smedley RC, Schall WD, Kruger JM. Acquired proximal renal tubular dysfuncction in 9 Labrador Retrievers with copper-associated hepatitis (2006-2012). *J Vet Intern Med.* 2013;27:491-499.

9. Mandigers PJ, van den Ingh TS, Bode P, et al. Association between liver copper concentration and subclinical hepatitis in Doberman Pinschers. *J Vet Intern Med.* 2004;18:647-650.

10. Thornburg LP, Shaw D, Dolan M, et al. Hereditary copper toxicity in West Highland White Terriers. *Vet Path.* 1986;23:148-154.

11. Webb CB, Twedt DC, Meyer DJ. Copper-associated liver disease in Dalmatians: a review of 10 dogs (1999-2001). *J Vet Intern Med.* 2002;16:665-668.

12. Appleman EH, Cianciolo R, Mosencos ME, et al. Copper-associated chronic hepatitis in 3 dogs. *J Vet Intern Med.* 2006;22:1038-1042.

13. Riffkin J, Miller MD. Copper-associated hepatitis in a Pembroke Welsh corgi. *Can Vet J.* 2014;55:573-576.

14. Fieten H, Gill Y, Martin AJ, et al. The Menkes and Wilson disease genes counteract in copper toxicity in Labrador retrievers: a new canine model for copper-metabolism disorders. *Dis Model Mech.* 2016;9:25-38.

15. Fieten H, Hooijer-Nouwens BD, Biourge VC, et al. Association of dietary copper and zinc levels with hepatic copper and zinc concentration in Labrador Retrievers. *J Vet Intern Med.* 2012;26:1274-1280.

16. van De Sluis B, Rothuizen J, Pearson PL, et al. Identification of a new copper metabolism gene by positional cloning in a purebred dog population. *Hum Mol Genet.* 2002;11:165-173.

17. Brewer GJ, Dick RD, Schall W, et al. Use of zinc acetate to treat copper toxicity in dogs. *J Am Vet Med Assoc.* 1992;201:564-568.

18. Hoffmann G, Jones PG, Biourge V, et al. Dietary management of hepatic copper accumulation in Labrador Retrievers. *J Vet Intern Med.* 2009;23:957-963.

19. Fieten H, Biourge VC, Watson AL, Leegwater PAJ, van den Ingh TS, Rothuizen J. Dietary management of laboratory retrievers with subclinical copper hepatic accumulation. *J Vet Intern Med.* 2015;29:822-827.

20. Walshe JM. Penicillamine: a new oral therapy for Wilson’s disease. *Am J Med.* 1956;2:487-495.

21. Hoffmann G. Copper-Associated Hepatitis In Labrador Retrievers: Clinical Characterization, Treatment, and Molecular Analysis [PhD thesis]. Faculty of Veterinary Medicine, Utrecht University; 2008. https://dspace.library.uu.nl/bitstream/handle/1874/27798/hoffmann.pdf?sequence=1

22. Fieten H, Dirksen K, van den Ingh TS, et al. D-penicillamine treatment of copper-associated hepatitis in Labrador retrievers. *Vet J.* 2013;196:522-527.

23. Langlois DK, Lehner AF, Buchweitz JP, et al. Pharmacokinetics and relative bioavailability of D-penicillamine in fasted and nonfasted dogs. *J Vet Intern Med.* 2013;27:1071-1076.

24. Brewer GJ, Askari F, Dick RB, et al. Treatment of Wilson’s disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine. *Clin North Am Small Anim Pract.* 2013;28:1071-1076.

25. Humphries WR, Morrice PC, Brenner I. A convenient method for the treatment of chronic copper poisoning in sheep using subcutaneous ammonium tetrathiomolybdate. *Vet Rec.* 1988;123:51-53.

26. Klein D, Arora U, Lichtmanegger J, Finckh M, Heinzmann U, Summer KH. Tetrathiomolybdate in the treatment of acute hepatitis in an animal model for Wilson disease. *J Hepatol.* 2004;40:409-416.

27. Suzuki KT. Selective removal of copper accumulating in a form bound to metallothionein in the liver of LEC rats by tetrathiomolybdate. *J Trace Elem Exp Med.* 1997;10:101-109.

28. Chan CM, Langlois DK, Buchweitz JP, et al. Pharmacologic evaluation of ammonium tetrathiomolybdate after intravenous and oral administration in healthy dogs. *Am J Vet Res.* 2015;76:445-453.

29. Larson MM. Ultrasound imaging of the hepatobiliary system and pancreas. *Vet Clin North Am Small Anim Pract.* 2016;46:453-480.

30. Center SA, McDonough SP, Bogdanovic L. Digital image analysis of rhodanine-stained liver biopsy specimens for calculation of hepatic copper concentrations in dogs. *Am J Vet Res.* 2013;74:1474-1480.

31. van den Ingh TSGAM, Van Winkle TJ, Cullen JM, et al. Morphological classification of parenchymal disorders of the canine and feline liver. In: Rothuizen J, Cullen JM, eds. *WSAVA Standards for Clinical and Histological Diagnosis of Canine and Feline Liver Diseases.* 1st ed. Philadelphia: Saunders Elsevier; 2006:65-101.

32. Brewer GJ, Dick RD, Yuzbashyan-Gurkin V, Tankanow R, Young AB, Kluin KJ. Initial therapy of patients with Wilson’s disease with tetrathiomolybdate. *Arch Neurol.* 1991;48:42-47.

33. Kent MS, Madewell BR, Dank G, Dick R, Merajver SD, Brewer GJ. An anticopper antiangiogenic approach for advanced cancer in spontaneously occurring tumors using tetrathiomolybdate: a pilot study in a canine animal model. *J Trace Elem Exp Med.* 2004;17:9-20.

34. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAIR Cooperative Study Group. *Hepatology.* 1996;24:289-293.

35. Ishak KG. Pathologic features of chronic hepatitis. A review and update. *Am J Clin Pathol.* 2000;113:40-55.

36. Raghu C, Ekena J, Cullen JM, Webb CB, Trepanier LA. Evaluation of potential serum biomarkers of hepatic fibrosis and necroinflammatory activity in dogs with liver disease. *J Vet Intern Med.* 2018;32:1009-1018.

37. Rolfe DS, Twedt DC. Copper-associated hepatopathies in dogs. *Vet Clin North Am Small Anim Pract.* 1995;25:399-417.

38. Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. Wilson’s disease. *Lancet.* 2007;369:397-408.

39. Brewer GJ. Zinc and tetrathiomolybdate for the treatment of Wilson’s disease and the potential efficacy of anticopper therapy in a wide variety of diseases. *Metallomics.* 2009;1:199-206.

40. Brewer GJ, Askari F, Lorincz MT, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. *Arch Neurol.* 2006;63:521-527.

41. Brewer GJ, Merajver SD. Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper—a review. *Integr Cancer Ther.* 2002;1:327-337.

42. Auza N, Braun JP, Benard P, Thouvenot JP, Rico AG. Hematological and plasma biochemical disturbances in experimental molybdenum toxicity in sheep. *Vet Hum Toxicol.* 1989;31:535-537.

43. Haywood S, Dincer Z, Holding J, Parry NM. Metal (molybdenum, copper) accumulation and retention in brain, pituitary and other organs of ammonium tetrathiomolybdate-treated sheep. *Br J Nutr.* 1998;79:329-331.

44. Haywood S, Dincer Z, Jasnabi B, Loughran MJ. Molybdenum-associated pituitary endocrinopathy in sheep treated with ammonium tetrathiomolybdate. *J Comp Pathol.* 2004;130:21-31.

45. Quinn JF, Harris CJ, Cobb KE, et al. A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer’s disease. *J Alzheimers Dis.* 2010;21:903-914.

46. Xu M, Casio M, Range DE, Sosa JA, Counter CM. Copper chelation as targeted therapy in a mouse model of oncogenic BRAF-driven papillary thyroid cancer. *Clin Cancer Res.* 2018;24:4271-4281.

47. Weiss KH, Askari FK, Czlonkowska A, et al. Bis-choline tetrathiomolybdate in patients with Wilson’s disease: an open-label, multicentre, phase 2 study. *Lancet Gastroenterol Hepatol.* 2017;2:869-876.

How to cite this article: Langlois DK, Quenrub JR, Schall WD, Nelson NC, Smedley RC. Ammonium tetrathiomolybdate treatment of copper-associated hepatopathy in dogs. *J Vet Intern Med.* 2019;33:1336–1343. https://doi.org/10.1111/jvim.15474